Evidence map›Paper›PMID 32089130›Full record

ArticleFluids and barriers of the CNS2020

Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.

Georg Pilz, Irma Sakic, Peter Wipfler, Jörg Kraus, Elisabeth Haschke-Becher, Wolfgang Hitzl, Eugen Trinka, Andrea Harrer

Open access · goldAbstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. A framework for blood biomarker discovery in MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
    Review
  3. Review
  4. Review
  5. Transcriptomic response toMicrobiology spectrum · 2026
    Article
  6. Article
  7. Infection and immunity · 2026
    Review
  8. Age-related changes in diurnal expression of inflammatory mediators in the brain and peripheral blood of male and female mice.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  9. Serum cytokines in periodontal diseases.Periodontology 2000 · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. [Recent research on cytokines associated with anti-N-methyl-D-aspartate receptor encephalitis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Review
  19. Article
  20. Experimental laboratory biomarkers in multiple sclerosis.Wiener medizinische Wochenschrift (1946) · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Georg PilzDepartment of Neurology, Paracelsus Medical University, Ignaz-Harrer-Str 79, Salzburg, 5020, Austria.
Irma SakicDepartment of Neurology, Paracelsus Medical University, Ignaz-Harrer-Str 79, Salzburg, 5020, Austria.
Peter WipflerDepartment of Neurology, Paracelsus Medical University, Ignaz-Harrer-Str 79, Salzburg, 5020, Austria.
Jörg KrausDepartment of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
Elisabeth Haschke-BecherDepartment of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
Wolfgang HitzlResearch Office, Biostatistics, Paracelsus Medical University, Salzburg, Austria.
Eugen TrinkaDepartment of Neurology, Paracelsus Medical University, Ignaz-Harrer-Str 79, Salzburg, 5020, Austria.
Andrea HarrerDepartment of Neurology, Paracelsus Medical University, Ignaz-Harrer-Str 79, Salzburg, 5020, Austria. a.harrer@salk.at.ORCID http://orcid.org/0000-0001-7717-6125
Paracelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeElevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and "leaking" of CXCL13 from blood across dysfunctional brain barriers is a possible source. The aim was to clarify the relation between CXCL13 concentrations in CSF, CXCL13 concentrations in serum and blood-CSF barrier (BCSFB) function for a correct interpretation of the intrathecal origin of CXCL13.

methodsWe retrospectively analyzed CXCL13 of banked CSF/serum samples (n = 69) selected from patient records and categorized the CSF CXCL13 elevations as CXCL13 negative (< 30 pg/ml), low (30-100 pg/ml), medium (101-250 pg/ml), or high (> 250 pg/ml). CXCL13 concentrations in CSF and serum and the corresponding CSF/serum CXCL13 quotients (Qcxcl13) were compared to CSF/serum albumin quotients (QAlb) as a measure for BCSFB function. The CXCL13 negative category included two subgroups with normal and dysfunctional BCSFB.

resultsSerum CXCL13 concentrations were similar across categories with median levels around 100 pg/ml but differed between individuals (29 to > 505 pg/ml). Despite clear evidence in serum, CXCL13 was detectable only at trace amounts (medians 3.5 and 7.5 pg/ml) in CSF of the two CXCL13 negative subgroups irrespective of a normal or pathological QAlb. Moreover, we found no association between CSF and serum CXCL13 levels or between QAlb and CSF CXCL13 levels in any of the CSF CXCL13-delineated categories. CXCL13 apparently does not "leak" from blood into CSF. This implies an intrathecal origin also for low CSF CXCL13 levels and a caveat for analyzing the Qcxcl13, because higher serum than CSF concentrations arithmetically depress the Qcxcl13 resulting in misleadingly low CSF/serum quotients.

conclusionWe demonstrated that CXCL13 does not cross from blood into CSF, not even during severe BCSFB dysfunction. CSF CXCL13 elevations therefore most likely always are CNS-derived, which highlights their relevance as indicator of inflammatory CNS processes. We recommend data should not be corrected for BCSFB permeability (QAlb) and not to calculate CSF/serum quotients for CXCL13 as these may introduce error.

Indexed as

Central Nervous System DiseasesInflammationChemokine CXCL13HumansRetrospective StudiesChemokine CXCL13CXCL13 protein, humanBiomarkerBlood–CSF-barrierCerebrospinal fluidChemokineCSF/serum quotientsCXCL13Inflammation

Identifiers

PMID32089130
PMCPMC7038591
OpenAlexW3012710285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.